<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cel-sci Corporation — News on 6ix</title>
<link>https://6ix.com/company/cel-sci-corporation</link>
<description>Latest news and press releases for Cel-sci Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Feb 2026 14:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cel-sci-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d747f951cc36e4753330a4.webp</url>
<title>Cel-sci Corporation</title>
<link>https://6ix.com/company/cel-sci-corporation</link>
</image>
<item>
<title>CEL-SCI Reports Fiscal First Quarter 2026 Results</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-first-quarter-2026-results</guid>
<pubDate>Wed, 18 Feb 2026 14:00:00 GMT</pubDate>
<description>VIENNA, Va., February 18, 2026--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.</description>
</item>
<item>
<title>CEL-SCI Reports Fiscal 2025 Results</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-2025-results</guid>
<pubDate>Mon, 29 Dec 2025 14:00:00 GMT</pubDate>
<description>VIENNA, Va., December 29, 2025--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.</description>
</item>
<item>
<title>CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-presentation-at-ld-micro-main-event-available-on-tuesday-october-21-2025</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-presentation-at-ld-micro-main-event-available-on-tuesday-october-21-2025</guid>
<pubDate>Mon, 20 Oct 2025 13:00:00 GMT</pubDate>
<description>Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro "Main Event" Investor Conference on October 21, 2025. You can register to watch the virtual presentation at 9:30 a.m. PST by following this link: https://ldmicrocasts.com/#register.Mr. Kersten will deliver a 20-minute corporate presentation...</description>
</item>
<item>
<title>CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-corporation-to-present-at-ld-micro-main-event-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-corporation-to-present-at-ld-micro-main-event-investor-conference</guid>
<pubDate>Fri, 10 Oct 2025 12:00:00 GMT</pubDate>
<description>Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro "Main Event" Investor Conference on October 21, 2025 at 9:30 a.m. PST. The Conference is taking place at the Hotel Del Coronado in San Diega, CA from October 19-21, 2025.Mr. Kersten will deliver a 20-minute corporate presentation highlighting the...</description>
</item>
<item>
<title>CEL-SCI Announces Closing of $10 Million Public Offering</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-closing-of-dollar10-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-closing-of-dollar10-million-public-offering</guid>
<pubDate>Fri, 29 Aug 2025 16:52:00 GMT</pubDate>
<description>VIENNA, Va., August 29, 2025--CEL-SCI announces closing of $10 million public offering.</description>
</item>
<item>
<title>CEL-SCI Announces Pricing of $10 Million Public Offering</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-pricing-of-dollar10-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-pricing-of-dollar10-million-public-offering</guid>
<pubDate>Thu, 28 Aug 2025 02:35:00 GMT</pubDate>
<description>VIENNA, Va., August 28, 2025--CEL-SCI announces pricing of $10 million public offering.</description>
</item>
<item>
<title>CEL-SCI Announces Proposed Public Offering</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-proposed-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-proposed-public-offering</guid>
<pubDate>Wed, 27 Aug 2025 21:25:00 GMT</pubDate>
<description>VIENNA, Va., August 27, 2025--CEL-SCI announces proposed public offering.</description>
</item>
<item>
<title>CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-third-quarter-2025-financial-results</guid>
<pubDate>Thu, 14 Aug 2025 14:45:00 GMT</pubDate>
<description>VIENNA, Va., August 14, 2025--CEL-SCI reports fiscal third quarter 2025 financial results.</description>
</item>
<item>
<title>CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-scis-multikine-head-and-neck-cancer-immunotherapy-breakthrough-medicine-designation-filed-in-saudi-arabia-allows-for-patient-access-and-reimbursementsale-upon-granting-of-the-designation-which-takes-approximately-60-days-based-on-sfda-timeline</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-scis-multikine-head-and-neck-cancer-immunotherapy-breakthrough-medicine-designation-filed-in-saudi-arabia-allows-for-patient-access-and-reimbursementsale-upon-granting-of-the-designation-which-takes-approximately-60-days-based-on-sfda-timeline</guid>
<pubDate>Wed, 13 Aug 2025 13:15:00 GMT</pubDate>
<description>VIENNA, Va., August 13, 2025--CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.</description>
</item>
<item>
<title>CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-closing-of-dollar57-million-offering-priced-at-the-market-under-nyse-american-rules</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-closing-of-dollar57-million-offering-priced-at-the-market-under-nyse-american-rules</guid>
<pubDate>Mon, 14 Jul 2025 20:05:00 GMT</pubDate>
<description>VIENNA, Va., July 14, 2025--CEL-SCI announces closing of $5.7 million offering priced at-the-market under NYSE American rules.</description>
</item>
<item>
<title>CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-pricing-of-dollar57-million-offering-priced-at-the-market-under-nyse-american-rules</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-pricing-of-dollar57-million-offering-priced-at-the-market-under-nyse-american-rules</guid>
<pubDate>Fri, 11 Jul 2025 16:16:00 GMT</pubDate>
<description>VIENNA, Va., July 11, 2025--CEL-SCI announces pricing of $5.7 million offering priced at-the-market under NYSE American rules.</description>
</item>
<item>
<title>CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-to-sign-partnership-agreement-with-leading-saudi-arabian-pharma-company-for-multikine-in-the-treatment-of-head-and-neck-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-to-sign-partnership-agreement-with-leading-saudi-arabian-pharma-company-for-multikine-in-the-treatment-of-head-and-neck-cancer</guid>
<pubDate>Fri, 11 Jul 2025 13:15:00 GMT</pubDate>
<description>VIENNA, Va., July 11, 2025--CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.</description>
</item>
<item>
<title>CEL-SCI Announces Closing of Public Offering</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-closing-of-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-closing-of-public-offering</guid>
<pubDate>Fri, 23 May 2025 20:05:00 GMT</pubDate>
<description>VIENNA, Va., May 23, 2025--CEL-SCI announces closing of public offering.</description>
</item>
<item>
<title>CEL-SCI Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-pricing-of-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-pricing-of-public-offering</guid>
<pubDate>Thu, 22 May 2025 00:14:00 GMT</pubDate>
<description>VIENNA, Va., May 22, 2025--CEL-SCI announces pricing of public offering.</description>
</item>
<item>
<title>CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-scis-multikine-investigational-cancer-medicine-potentially-available-for-commercialization-by-summer-2025-in-saudi-arabia</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-scis-multikine-investigational-cancer-medicine-potentially-available-for-commercialization-by-summer-2025-in-saudi-arabia</guid>
<pubDate>Wed, 21 May 2025 12:00:00 GMT</pubDate>
<description>VIENNA, Va., May 21, 2025--CEL-SCI’S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.</description>
</item>
<item>
<title>CEL-SCI Announces Combination of Common Stock</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-combination-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-announces-combination-of-common-stock</guid>
<pubDate>Mon, 19 May 2025 18:40:00 GMT</pubDate>
<description>VIENNA, Va., May 19, 2025--CEL-SCI announces combination of common stock.</description>
</item>
<item>
<title>CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-second-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-reports-fiscal-second-quarter-2025-financial-results</guid>
<pubDate>Thu, 15 May 2025 13:00:00 GMT</pubDate>
<description>VIENNA, Va., May 15, 2025--CEL-SCI reports fiscal second quarter 2025 financial results.</description>
</item>
<item>
<title>CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market</title>
<link>https://6ix.com/company/cel-sci-corporation/news/cel-sci-to-file-for-regulatory-approval-of-multikine-in-saudi-arabiapursuing-local-partnerships-for-commercialization-and-manufacturing-to-serve-middle-east-and-north-africa-market</link>
<guid isPermaLink="true">https://6ix.com/company/cel-sci-corporation/news/cel-sci-to-file-for-regulatory-approval-of-multikine-in-saudi-arabiapursuing-local-partnerships-for-commercialization-and-manufacturing-to-serve-middle-east-and-north-africa-market</guid>
<pubDate>Wed, 23 Apr 2025 12:30:00 GMT</pubDate>
<description>VIENNA, Va., April 23, 2025--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market</description>
</item>
</channel>
</rss>